image: Through detailed explanation and online demos, the event will provide an exclusive look into the latest advancements and innovations within the Pharma.AI platform, which comprises Biology42, Chemistry42, Medicine42 and Science42.
Credit: Insilico Medicine
CAMBRIDGE, Mass., Nov 14, 2024 --- Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, will be hosting Pharma.AI Week featuring in-depth webinar series from November 19-21. Through detailed explanation and online demos, the event will provide an exclusive look into the latest advancements and innovations within the Pharma.AI platform, which comprises Biology42, Chemistry42, Medicine42 and Science42. Anyone interested in attending can register here.
Join us at Pharma.AI Week 2024 and witness the new Pharma.AI suite boasting PandaOmics, the target discovery engine with a broader data access, Science42: DORA the multi-agent writing assistant with more powerful search functions and better transparency, Chemistry42, the generative AI small molecules drug discovery platform with data input upgrades and customized models, and Generative Biologics, the de novo protein engineering platform with newly added template-based generation workflow. Moreover, Retrosynthesis designed for synthetic route discovery will be making its debut as a novel application under Chemistry42.
Experienced speakers for the webinar series include Petrina Kamya, PhD, Vice President and Global Head of AI Platforms and President of Insilico Medicine Canada, Jan Szollos, Senior Director of AI Platforms Business Development, and Daniil Polykovskiy, PhD, Senior Director of Technology.
"I am happy to witness another series of Pharma.AI updates, which often happens once or twice a year," says Petrina Kamya, PhD, Vice President and Global Head of AI Platforms and President of Insilico Medicine Canada. "From biology, chemistry, medicine to science, we hope to empower researchers and scientists with the tools they need to make faster, more accurate discoveries, for the development of life-saving therapies, and even a better world."
Up until now, 11 of the world's Top 20 pharmaceutical companies are officially using Insilico’s Pharma.AI platform, which has successfully empowered Insilico’s long-term R&D collaborations with Fosun Pharma and Sanofi, with upfront payments of $13 million and $21 million, respectively. In addition, peer-reviewed papers with Pharma.AI contribution are published in well-known journals including Chemical Science, Nature Communications, and JCIM.
"Insilico Medicine was founded at the time when generative AI first revealed its potential in scientific research, and we are hoping to expand AI advantage to more fields that matter," says Alex Zhavoronkov, Founder and CEO of Insilico Medicine. "We believe that by sharing our knowledge and advancements, we can foster a collaborative environment that accelerates the development of novel drugs and cutting-edge innovation."
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 20 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 10 molecules.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001-055, the company’s lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001-055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
www.insilico.com